Dr. Reddy's Q2FY26 Earnings Call Transcript
Dr. Reddy's Q2FY26 results: Revenue ₹8,805 crore, up 9.8% YoY; PAT ₹1,437 crore, up 14% YoY. Awaiting court decision on Semaglutide patent challenge in India. BLA submission for Abatacept expected by Dec 2025.
The financial results indicate steady performance and growth in certain areas. The ongoing litigation and regulatory inspections could have potential future implications.
The announcement primarily contains factual information regarding the earnings call and financial results. While there is growth in some areas, there are also challenges noted, resulting in a neutral sentiment.
* Dr. Reddy's Laboratories Ltd. announced the transcript of its Q2FY26 earnings call held on October 24, 2025. * Consolidated revenues for the quarter stood at ₹8,805 crore ($992 million), a growth of 9.8% year-over-year. * EBITDA for the quarter stood at ₹2,351 crore ($265 million), an increase of 3% year-over-year. * Profit after tax attributable to equity holders of the parent for the quarter stood at ₹1,437 crore ($162 million), a growth of 14% year-over-year. * Diluted EPS for the quarter is ₹17.25. * The company is challenging the patents for Semaglutide in India and is awaiting a decision from the High Court in Delhi. * Expects to submit the BLA for Abatacept by the end of December 2025. * The US FDA conducted a Pre-Approval Inspection at the Bachupally biologics facility and issued a Form 483 with five observations. * Management Commentary: Erez Israeli mentioned that the company is focused on growing the base business, key pipeline assets like Semaglutide and Abatacept, improving operational efficiency, and exploring partnerships and acquisitions.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.